Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HBB | P68871 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25424836 | 0.79 | ALDH1A1 (0.64) | MAPTHPGDALDH1A1RAB9ANPC1 | |
| SCHEMBL22367578 | 0.78 | ALDH1A1 (0.61) | MAPTHPGDALDH1A1RAB9ANPC1 | |
| SCHEMBL303244 | 0.78 | ALDH1A1 (0.61) | MAPTHPGDALDH1A1RAB9ANPC1 | |
| SCHEMBL767242 | 0.78 | KMT2A (0.59) | MAPTHPGDALDH1A1RAB9ANPC1 | |
| SCHEMBL10350172 | 0.77 | ALDH1A1 (0.55) | MAPTHPGDALDH1A1RAB9ANPC1 | |
| SCHEMBL2639458 | 0.76 | ALDH1A1 (0.59) | MAPTHPGDALDH1A1RAB9ANPC1 | |
| SCHEMBL774179 | 0.76 | GSK3B (0.61) | MAPTHPGDALDH1A1RAB9ANPC1 | |
| SCHEMBL6014455 | 0.76 | ALDH1A1 (0.59) | MAPTHPGDALDH1A1RAB9ANPC1 | |
| SCHEMBL10001068 | 0.76 | GSK3B (0.61) | MAPTHPGDALDH1A1RAB9ANPC1 | |
| SCHEMBL2639461 | 0.76 | ALDH1A1 (0.59) | MAPTHPGDALDH1A1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2877457-B1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | SOVA PHARMACEUTICALS INC (US) | 2020-09-23 | — | — | EP | disclosed |
| EP-2877457-B1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | SOVA PHARMACEUTICALS INC (US) | 2020-09-23 | — | — | EP | disclosed |
| CN-104662007-B | Cystathionine gamma lyase (CSE) inhibitor | 索瓦制药公司 | 2018-03-16 | — | — | CN | disclosed |
| US-20170327478-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | SOVA PHARMACEUTICALS, INC. | 2017-11-16 | — | — | US | disclosed |
| US-20170327478-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | SOVA PHARMACEUTICALS, INC. | 2017-11-16 | — | — | US | disclosed |
| US-20170327478-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | SOVA PHARMACEUTICALS, INC. | 2017-11-16 | — | — | US | disclosed |
| US-9725426-B2 | Cystathionine-γ-lyase (CSE) inhibitors | SOVA PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725426-B2 | Cystathionine-γ-lyase (CSE) inhibitors | SOVA PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725426-B2 | Cystathionine-γ-lyase (CSE) inhibitors | SOVA PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20150272934-A1 | USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS | SOVA PHARMACEUTICALS, INC. | 2015-10-01 | — | — | US | disclosed |
| EP-2877457-A1 | CYSTATHIONINE- -LYASE (CSE) INHIBITORS | Sova Pharmaceuticals, Inc. (US) | 2015-06-03 | — | — | EP | disclosed |
| EP-2877175-A2 | USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS | Sova Pharmaceuticals, Inc. (US) | 2015-06-03 | — | — | EP | disclosed |
| CN-104662007-A | Cystathionine-upsilon-lyase (cse) inhibitors | SOVA PHARMACEUTICALS INC | 2015-05-27 | — | — | CN | disclosed |
| WO-2014018571-A2 | USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS | SOVA PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | WO | disclosed |
| WO-2014018571-A2 | USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS | SOVA PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | WO | disclosed |
| WO-2014018570-A1 | CYSTATHIONINE-Υ-LYASE (CSE) INHIBITORS | SOVA PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | WO | disclosed |
| WO-2014018570-A1 | CYSTATHIONINE-Υ-LYASE (CSE) INHIBITORS | SOVA PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | WO | disclosed |
| US-4053470-A | BACTERICIDES, ANTIBIOTICS | PARKE, DAVIS & COMPANY (US) | 1977-10-11 | — | — | US | disclosed |
| US-3954734-A | PENICILLIN AND CEPHALOSPORIN TYPE | PARKE, DAVIS & COMPANY | 1976-05-04 | — | — | US | disclosed |
| US-3951982-A | Trialkylsilyl esters of 6(substituted amino)phenyl-1,-dihydro-2-oxonicotinic acid, methods for their production and conversion to the corresponding acid chlorides | PARKE, DAVIS & COMPANY | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327478-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | CBS, CTH, BHMT | MAPT 2893/4885HPGD 452/4885ALDH1A1 954/4885 |
| US-20150272934-A1 | USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS | HIF1AN, CBS, COXFA4L2 | MAPT 3866/4885HPGD 501/4885ALDH1A1 974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.